These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22463731)

  • 1. Mineralocorticoid receptor antagonist for renal protection.
    Ma TK; Szeto CC
    Ren Fail; 2012; 34(6):810-7. PubMed ID: 22463731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
    Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A; Saruta T; Funder JW
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
    Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
    Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC; Navis G; Laverman GD
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone, a new selective aldosterone blocker.
    McMahon EG
    Curr Pharm Des; 2003; 9(13):1065-75. PubMed ID: 12678858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
    Ryan MJ; Tuttle KR
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
    Tylicki L; Lizakowski S; Rutkowski B
    J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone blockade in CKD: emphasis on pharmacology.
    Schwenk MH; Hirsch JS; Bomback AS
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):123-32. PubMed ID: 25704349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
    Onozato ML; Tojo A; Kobayashi N; Goto A; Matsuoka H; Fujita T
    Nephrol Dial Transplant; 2007 May; 22(5):1314-22. PubMed ID: 17324946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin angiotensin antagonists normalize aberrant activation of epithelial sodium channels in sodium-sensitive hypertension.
    Ushio-Yamana H; Minegishi S; Ishigami T; Araki N; Umemura M; Tamura K; Maeda E; Kakizoe Y; Kitamura K; Umemura S
    Nephron Exp Nephrol; 2012; 122(3-4):95-102. PubMed ID: 23594971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.